Amgen will be holding its shareholder meeting soon. Supposedly they will announce their first ever dividend for its investors. Analysts say they and investors will be looking for news of pipeline projects. Acerbicly one comments, "They have been talking about Phase II's for 5 years and nothing has come of it." AMG479, a new drug for pancreatic cancer, is the top pipeline candidate. It's been dubbed a blockbuster contender. We await the news. See Fierce Biotech.
Posted by Bruce Lehr April 18th 2011.